Patents Assigned to Baker IDI Heart and Diabetes Institute Holdings Limited
-
Patent number: 10835127Abstract: An apparatus detects atherosclerotic plaques. The apparatus includes an electronic processing device that determines a level of fluorescence sensed by a sensor at a second infrared wavelength in response to exposure of at least part of an artery to radiation at a first infrared wavelength and determines a fluorescence indicator using the level of fluorescence. The fluorescence indicator is indicative of the presence, absence or degree of an atherosclerotic plaque.Type: GrantFiled: April 12, 2013Date of Patent: November 17, 2020Assignee: BAKER IDI HEART & DIABETES INSTITUTE HOLDINGS LIMITEDInventors: Karlheinz Peter, Nay Min Htun, Yung-Chih Chen
-
Patent number: 9365650Abstract: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.Type: GrantFiled: January 2, 2008Date of Patent: June 14, 2016Assignee: Baker IDI Heart and Diabetes Institute Holdings LimitedInventor: Karlheinz Peter
-
Patent number: 9255935Abstract: The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system.Type: GrantFiled: June 30, 2015Date of Patent: February 9, 2016Assignee: BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITEDInventors: Peter John Meikle, Izhak Haviv, Bronwyn Anne Kingwell, Justin Bedo, Benjamin Goudey
-
Patent number: 9110086Abstract: The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system.Type: GrantFiled: November 26, 2010Date of Patent: August 18, 2015Assignee: BAKER IDI HEART AND DIABETES INSTITUTE HOLDINGS LIMITEDInventors: Peter John Meikle, Izhak Haviv, Bronwyn Anne Kingwell, Justin Bedo, Benjamin Goudey
-
Publication number: 20140328908Abstract: The present invention relates to oral controlled-release formulations of 5-(pyridinyl)-2(1H)-pyridinone compounds and their use in the treatment of a subject with heart failure, a stage, class or manifestation of heart failure, or at risk of developing or exhibiting symptoms of heart failure. The formulations of the invention release the compounds in the range of between 0.1 ?g/kg body weight/minute and 20 ?g/kg body weight/minute.Type: ApplicationFiled: August 16, 2012Publication date: November 6, 2014Applicant: Baker IDI Heart & Diabetes Institute Holdings LimitedInventors: David Martin Kaye, Guy Krippner, Geetha Thanga Mariappan
-
Publication number: 20140243502Abstract: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.Type: ApplicationFiled: January 2, 2008Publication date: August 28, 2014Applicant: Baker IDI Heart and Diabetes Institute Holdings LimitedInventor: Karlheinz Peter
-
Publication number: 20130023054Abstract: The present invention relates generally to the field of diagnostic and prognostic assays for heart disease. More particular, the present invention provides an assay for diagnosing the presence or extent of development of heart disease or its classification or state thereof. The assay of the present invention is also useful in the stratification of a subject with respect to a risk of developing heart disease. The assay of the present invention is also capable of integration into pathology architecture to provide a diagnostic and reporting system.Type: ApplicationFiled: November 26, 2010Publication date: January 24, 2013Applicant: Baker IDI Heart and Diabetes Institute Holdings LimitedInventors: Peter John Meikle, Izhak Haviv, Bronwyn Anne Kingwell, Justin Bedo, Benjamin Goudey
-
Publication number: 20090317329Abstract: The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.Type: ApplicationFiled: December 18, 2008Publication date: December 24, 2009Applicant: Baker IDI Heart & Diabetes Institute Holdings LimitedInventor: Karlheinz Peter
-
Publication number: 20090317330Abstract: Disclosed herein are compositions, methods, and kits for diagnosing or predicting a disease in a subject, for detecting activated platelets in a subject, and for treating a disease in a subject, wherein the diseases are mediated by platelet activation.Type: ApplicationFiled: December 22, 2008Publication date: December 24, 2009Applicant: Baker IDI Heart and Diabetes Institute Holdings LimitedInventor: Karlheinz Peter
-
Publication number: 20090291048Abstract: The present invention provides molecules capable of specifically binding the activated form of the beta-integrin Mac-1. The molecules may be provided in the form of peptides, polypeptides and single chained antibodies. The molecules may be used therapeutically for the treatment of disease mediated by Mac-1 (such as inflammation), or used diagnostically to locate sites of Mac-1 activity in the body.Type: ApplicationFiled: October 25, 2006Publication date: November 26, 2009Applicant: Baker IDI Heart and Diabetes Institute Holdings LimitedInventors: Karlheinz Peter, Steffen Eisenhardt, Meike Schwarz